TrialBasket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Trial details
- Registry ID
- NCT01953926
- Phase
- Phase 2
PBYI
Puma Biotechnology, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
4Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 MutationsNCT01953926 | PBYI | Phase 2 | Terminated | 2023-01-02Actual |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerNCT06095505 | PBYI | Phase 2 | Recruiting | 2027-10-30Estimated |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerNCT06369285 | PBYI | Phase 2 | Recruiting | 2027-12-30Estimated |
| A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)NCT07465757 | PBYI | Phase 2 | Recruiting | 2028-03-31Estimated |
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
Trial details
- Registry ID
- NCT06095505
- Phase
- Phase 2
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Trial details
- Registry ID
- NCT06369285
- Phase
- Phase 2
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Trial details
- Registry ID
- NCT07465757
- Phase
- Phase 2
Latest recorded trial changes
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
NCT07465757 · Puma Biotechnology, Inc.
Recruitment status
Recorded edit− Previous value
Not yet recruiting
+ Updated value
Recruiting
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
NCT06369285 · Puma Biotechnology, Inc.
Enrollment · participant count
Recorded edit− Previous value
count: 150; type: ESTIMATED
+ Updated value
count: 225; type: ESTIMATED
Primary completion date
Recorded edit− Previous value
2027-06-30
+ Updated value
2027-12-30
A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer
NCT06095505 · Puma Biotechnology, Inc.
Enrollment · participant count
Recorded edit− Previous value
count: 80; type: ESTIMATED
+ Updated value
count: 120; type: ESTIMATED
Primary completion date
Recorded edit− Previous value
2027-04-30
+ Updated value
2027-10-30